GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Price-to-Owner-Earnings

CRON (Cronos Group) Price-to-Owner-Earnings : (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Price-to-Owner-Earnings?

As of today (2024-12-15), Cronos Group's share price is $1.93. Cronos Group does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cronos Group's Price-to-Owner-Earnings or its related term are showing as below:

During the past 10 years, the highest Price-to-Owner-Earnings of Cronos Group was 47.30. The lowest was 1.82. And the median was 3.43.


CRON's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 26.825
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-15), Cronos Group's share price is $1.93. Cronos Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.12. Therefore, Cronos Group's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-15), Cronos Group's share price is $1.93. Cronos Group's EPS without NRI for the trailing twelve months (TTM) ended in was $0.07. Therefore, Cronos Group's PE Ratio without NRI for today is 28.81.

During the past 10 years, Cronos Group's highest PE Ratio without NRI was 76.67. The lowest was 28.81. And the median was 42.92.


Cronos Group Price-to-Owner-Earnings Historical Data

The historical data trend for Cronos Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Price-to-Owner-Earnings Chart

Cronos Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.50 - - - -

Cronos Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cronos Group's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cronos Group's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cronos Group's Price-to-Owner-Earnings falls into.



Cronos Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cronos Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.93/-0.09
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cronos Group  (NAS:CRON) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cronos Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cronos Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cronos Group Business Description

Traded in Other Exchanges
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Executives
Kamran Khan director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii officer: VP, Controller C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd. 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc. 10 percent owner 6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm officer: Chief Financial Officer 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik officer: General Manager (Israel) 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore officer: Chief Financial Officer C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022